Skip to main content

Table 3 Subgroup analyses

From: Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis

Variable

Subgroup

OS

1-year survival

3-year survival

5-year survival

Overall morbidity

Major morbidity

PHLF

Mortality

R0 resection

Region

Western

HR = 1.34; 95% CI, 0.95–1.89; P = 0.097; n = 4

RR = 0.90; 95% CI, 0.72–1.13; P = 0.354

n = 2

RR = 0.93; 95% CI, 0.73–1.19; P = 0.552

n = 3

RR = 0.70; 95% CI, 0.52–0.94; P = 0.018

n = 4

RR = 0.70; 95% CI, 0.57–0.87; P = 0.001

n = 2

RR = 0.62; 95% CI, 0.42–0.91; P = 0.015

n = 2

RR = 0.40; 95% CI, 0.09–1.82; P = 0.233

n = 1

RR = 0.39; 95% CI, 0.17–0.88; P = 0.024

n = 3

RR = 0.87; 95% CI, 0.76–0.99; P = 0.038

n = 3

 

Eastern

HR = 1.19; 95% CI, 0.82–1.73; P = 0.362; n = 6

RR = 1.08; 95% CI, 0.93–1.24; P = 0.315

n = 3

RR = 0.96; 95% CI, 0.77–1.19; P = 0.681

n = 4

RR = 0.97; 95% CI, 0.72–1.30; P = 0.836

n = 4

RR = 0.92; 95% CI, 0.74–1.14; P = 0.434

n = 2

RR = 0.88; 95% CI, 0.61–1.26; P = 0.477

n = 3

RR = 0.16; 95% CI, 0.05–0.55; P = 0.003

n = 3

RR = 0.42; 95% CI, 0.20–0.88; P = 0.021

n = 6

RR = 1.00; 95% CI, 0.90–1.10; P = 0.958

n = 4

Year of publication

≤2014

HR = 1.39; 95% CI, 0.92–2.10; P = 0.113; n = 3

RR = 0.90; 95% CI, 0.72–1.13; P = 0.354

n = 2

RR = 0.53; 95% CI, 0.29–0.96; P = 0.037

n = 1

RR = 0.63; 95% CI, 0.39–1.00; P = 0.051

n = 2

RR = 0.86; 95% CI, 0.61–1.20; P = 0.377

n = 1

n = 0

n = 0

RR = 0.32; 95% CI, 0.13–0.77; P = 0.011

n = 3

RR = 0.90; 95% CI, 0.78–1.04; P = 0.141

n = 2

 

>2014

HR = 1.20; 95% CI, 0.87–1.65; P = 0.276; n = 7

RR = 1.08; 95% CI, 0.93–1.24; P = 0.315

n = 3

RR = 0.99; 95% CI, 0.84–1.18; P = 0.917

n = 6

RR = 0.89; 95% CI, 0.70–1.12; P = 0.307

n = 6

RR = 0.81; 95% CI, 0.68–0.97; P = 0.018

n = 3

n = 5

n = 4

RR = 0.47; 95% CI, 0.23–0.96; P = 0.038

n = 6

RR = 0.97; 95% CI, 0.88–1.07; P = 0.582

n = 5

Cases

> 41cases

HR = 1.24; 95% CI, 0.92–1.66; P = 0.154; n = 3

RR = 1.08; 95% CI, 0.93–1.25; P = 0.303

n = 2

RR = 0.93; 95% CI, 0.72–1.21; P = 0.594

n = 2

RR = 0.84; 95% CI, 0.62–1.13; P = 0.248

n = 3

RR = 0.85; 95% CI, 0.70–1.03; P = 0.102

n = 3

RR = 0.76; 95% CI, 0.46–1.27; P = 0.295

n = 2

RR = 0.38; 95% CI, 0.11–1.32; P = 0.127

n = 2

RR = 0.32; 95% CI, 0.14–0.72; P = 0.006

n = 4

RR = 0.95; 95% CI, 0.85–1.06; P = 0.369

n = 4

≤ 41cases

HR = 1.35; 95% CI, 0.82–2.23; P = 0.231; n = 7

RR = 0.96; 95% CI, 0.77–1.19; P = 0.688

n = 3

RR = 0.95; 95% CI, 0.77–1.18; P = 0.656

n = 5

RR = 0.81; 95% CI, 0.61–1.08; P = 0.148

n = 5

RR = 0.74; 95% CI, 0.60–0.91; P = 0.004

n = 1

RR = 0.71; 95% CI, 0.52–0.97; P = 0.029

n = 3

RR = 0.12; 95% CI, 0.03–0.55; P = 0.006

n = 2

RR = 0.52; 95% CI, 0.24–1.10; P = 0.086

n = 5

RR = 0.94; 95% CI, 0.84–1.05; P = 0.289

n = 3

  1. Data are presented as HR or RR (95% CI); P value; number of included studies (n)
  2. Abbreviations: OS overall survival, PHLF postoperative liver failure